VivoSeq
Oncology

Non-Hodgkin Lymphoma

26

Pipeline Programs↗

9

Active Trials↗

12

Companies Involved↗

Non-Hodgkin Lymphoma is an emerging landscape with 26 programs across 12 companies. The most active players are Luminary Therapeutics, RECORDATI GROUP, Artiva Biotherapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

15/100

Mech. Concentration

15/100

Completion Rate

0/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Luminary Therapeutics

1 program

Phase 1R

RECORDATI GROUP

1 program

Phase 1A

Artiva Biotherapeutics, Inc.

1 program

Phase 1Incyte logo

Incyte

1 program

Phase 1E

Essen Biotech

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

21programs
Small molecule1048%
Monoclonal antibody838%
Antibody–drug conjugate15%
Protein / enzyme15%
Cell therapy15%

Modality classified for 85% of 26 pipeline programs.

Analysis

Trial Status

10

clinical trials

Active, not recruiting4 · 40%
Recruiting3 · 30%
Not yet recruiting2 · 20%
Withdrawn1 · 10%

Clinical Trials

Trial Activity

10 trials

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
Recruiting·Roche logoRoche·Phase 1·NCT05169515·121 enrolled
Phase 1 Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT05098613·68 enrolled
Pilot Safety-feasibility Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Recruiting·—·Phase 1·NCT06447376·20 enrolled
Phase I Trial of TmCD19-IL18 CAR T Cells in Patients With Relapsed or Refractory CD19+ Cancers
Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT05989204·26 enrolled
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
Active, not recruiting·AAbramson Cancer Center at Penn Medicine·Phase 2·NCT04827862·6 enrolled
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Active, not recruiting·AAcerta Pharma BV·Preclinical·NCT02180711·113 enrolled
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Active, not recruiting·Genmab logoGenmab·Phase 2·NCT05283720·264 enrolled
Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma
Not yet recruiting·PPaolo Caimi, MD·Phase 1·NCT07225439·15 enrolled
A Phase 1 Study of Allogeneic (γ/δ) BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Not yet recruiting·LLuminary Therapeutics·Phase 1·NCT07679919·27 enrolled
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study
Withdrawn·SStanford University·Preclinical·NCT05416554

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)